On November 8, 2022, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (ScienTech Medical) successfully listed on the Main Board of the Stock Exchange of Hong Kong, raising approximately HK$654.6 million (US$83.4 million) from a global offering of 22,455,000 H shares, or approximately HK$752.7 million (US$95.9 million) if the underwriters fully exercise their over-allotment option to purchase 3,368,000 additional H shares. Wilson Sonsini Goodrich & Rosati acted as U.S. and Hong Kong counsel to ScienTech Medical in the global offering and listing.
ScienTech Medical is a leading interventional medical device provider in China for congenital heart diseases, a major field of application for structural heart diseases. The company has a broad product portfolio covering occluder products, including primarily various CHD, PFO, and LAA occluder products and heart valve product candidates, including primarily aortic valve and mitral valve product candidates.
The Wilson Sonsini team representing ScienTech Medical in this transaction includes:
Corporate
Weiheng Chen
Dan Ouyang
Winfield Lau
Ke Li
Billy Yiu
Haoqian Chen
Yu Ma
Ziyue Zhu
Giselle Ma
Vincent Wang
Kelly Cheng
Ya Liu
Hera Poon
Kelvin Lam
Patents and Innovations
Richard Wang
Bo Chen
For more information, please see Lepu Medical’s news release.